WESTBROOK, Maine - IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the introduction of the IDEXX inVue Dx™ Cellular Analyzer. This new device is touted as a revolutionary tool for veterinary practices, designed to streamline the analysis of cytology and blood morphology tests.
The inVue Dx analyzer employs artificial intelligence (AI) and is said to deliver reference-laboratory quality results within 10 minutes, a significant reduction in time compared to traditional methods that can take upwards of 20 minutes. The technology behind this device allows for the examination of cells in their natural state, offering multidimensional images and potentially more accurate diagnostic insights.
Veterinary practices in the United States conduct an estimated 33 million cytology and morphology tests annually, which are essential for diagnosing various pet health issues. The inVue Dx analyzer aims to address the challenges associated with manual microscopy, such as time consumption, technique sensitivity, and subjective interpretation. By automating the process, the analyzer is designed to provide consistent, clinically actionable results, and when used in conjunction with IDEXX's ProCyte Dx or ProCyte One hematology analyzers, it can offer a comprehensive hematology picture during the patient visit.
The inVue Dx analyzer integrates seamlessly with IDEXX's suite of point-of-care analyzers, practice management systems, and VetConnect® PLUS, all powered by the IDEXX VetLab® Station. This integration is intended to help veterinarians interpret results, determine next steps, and ensure accurate billing for services rendered.
IDEXX's President and CEO, Jay Mazelsky, highlighted the inVue Dx analyzer as a testament to the company's commitment to innovation that enhances efficiency and diagnostic confidence for practitioners. The global launch of the inVue Dx analyzer is slated to begin in late 2024.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.